公开(公告)号：US20240168038A1

公开(公告)日：2024-05-23

申请号：US18283652

申请日：2022-03-25

申请人： RANDOX LABORATORIES ,  RANDOX TEORANTA

发明人： Ivan McConnell ,  Peter Fitzgerald ,  John Lamont ,  Ciaran Richarson ,  Matthew Griffin

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/4716 ,  G01N2333/70578 ,  G01N2800/347 ,  G01N2800/52

摘要： The current invention provides methods which can be implemented alongside clinical variables as risk prediction tools for improved prediction of CKD progression and mortality. Surprisingly it was found that decreased C3a-desArg was associated with adverse outcome in CKD, and when combined with increased STNFR1 and NGAL it gave an excellent predictor of progression to a composite endpoint in CKD patients.